Browse Studies — Arctuva

Phase 1

A Phase 1/2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule, in Subjects With Unresectable, Locally Advanced, or Metastatic Solid Tumors That Are Antigen-rich (START-001)

This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent and in co…

Advanced Solid TumorsGenital Neoplasm, FemaleUrogenital Neoplasms+11 more

Estimated

~$10 – $8,750

Marengo Therapeutics, Inc.NCT05592626

A Non-Significant Risk Specimen Collection Study to Obtain Vaginal Swab Samples for Algorithm Development and Testing

In this pilot study, prospectively acquired clinician-collected and participant-collected vaginal swab specimens will be obtained from up to 1000 individuals w…

Bacterial InfectionsBacterial Infections and MycosesInfections+10 more

Estimated

~$10 – $1,050

Nanopath, IncNCT07607470

Phase 2

A Phase II Double-blind, Placebo-controlled, Randomized Trial of Topical Artesunate Ointment for the Treatment of Patients With Vulvar High-grade Squamous Intraepithelial Lesions (Vulvar HSIL)

This is a phase II double-blind, placebo-controlled study of artesunate ointment for the treatment of HPV-associated vulvar HSIL (usual type vulvar intraepithe…

Vulvar DiseasesHPV InfectionVulvar HSIL+10 more

Estimated

~$10 – $8,750

Frantz Viral Therapeutics, LLCNCT06075264

Observational

Prospective Evaluation of Infectious Vulvovaginitis on Wound Complication Rates After Vulvar Excision for Premalignant Lesions

Primary: * To measure the rate of perioperative vulvovaginitis in a population of patients in central VA with non-malignant vulvar disease who require surgica…

VaginitisVulvar Diseases

Estimated

~$10 – $6,250

University of VirginiaNCT06070454